Researchers at the University of Waterloo have engineered bacteria to target and consume tumors from within, marking a significant advancement in cancer treatment. The bacteria, known as Clostridium sporogenes, thrive in oxygen-free environments, making them suitable for attacking solid tumors that are typically devoid of oxygen and filled with dead cells.
In a study published in the journal ACS Synthetic Biology, Professor Marc Aucoin, a chemical engineering expert, explained that the bacteria enter tumors, finding a nutrient-rich environment where they can grow. “Bacteria spores enter the tumor, finding an environment where there are lots of nutrients and no oxygen, which this organism prefers,” Aucoin stated. “So, we are now colonizing that central space, and the bacterium is essentially ridding the body of the tumor.”
This innovative approach aims to provide a viable alternative to conventional cancer therapies such as chemotherapy, radiation, and immunotherapy, which often come with significant side effects. Notably, bacteria can also help stimulate an immune response against cancer, enhancing their therapeutic potential.
The concept of using bacteria as a treatment is gaining traction in the scientific community. Christopher Johnston, a researcher in genomic medicine at the University of Texas, noted the potential of bacteria to overcome challenges associated with traditional cancer therapies. “Solid tumors, which account for the majority of adult cancers, can be notoriously treatment-resistant due to their complex microenvironment,” Johnston explained. “Harnessing the unique abilities of certain microbes may give us a new way to tackle those barriers.”
Challenges and Innovations in Bacterial Cancer Treatment
Despite the promising results, the research team faced challenges in ensuring the bacteria could survive near the tumor edges, where oxygen levels rise. To address this, they genetically modified the C. sporogenes to tolerate oxygen, allowing them to thrive even close to oxygen-rich areas. This adaptation was detailed in a 2023 study.
Furthermore, the researchers employed a technique known as “quorum sensing,” allowing the bacteria to activate oxygen-tolerance genes only after they have multiplied sufficiently within the tumor. The team also engineered the bacteria to produce a green fluorescent protein, which serves as a visual indicator that the bacteria have effectively colonized the tumor.
Using synthetic biology, the researchers constructed a system akin to an electrical circuit, but with DNA segments serving as the components. “Each piece has its job. When assembled correctly, they form a system that works in a predictable way,” said Brian Ingalls, a professor of applied mathematics at Waterloo.
Future Directions and Clinical Trials
While the current findings provide a strong proof of concept, further research is needed to explore the application of this treatment in humans. The team at the University of Waterloo is planning to combine their innovations regarding oxygen resistance and quorum sensing into a single bacterium for pre-clinical trials.
This groundbreaking research has the potential to revolutionize cancer treatment, offering hope for patients seeking alternatives to traditional therapies. As scientists continue to explore the therapeutic use of bacteria, the future of cancer treatment could see a significant and transformative shift.
